Revision as of 20:23, 5 March 2021 editPythagimedes (talk | contribs)Extended confirmed users1,234 edits not relevant or helpful for this specific articleTags: Mobile edit Mobile web edit Advanced mobile edit← Previous edit | Latest revision as of 16:29, 9 April 2021 edit undoBon courage (talk | contribs)Extended confirmed users66,214 edits boldly redirect since any mention makes more sense in target articleTag: New redirect | ||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
#REDIRECT ] | |||
{{Infobox person | |||
|name = Edward Tobinick | |||
|birth_place = ], US | |||
|nationality = American | |||
|known_for = Perispinal ] | |||
|alma_mater = ] (B.S. Biology, 1973)<br />] (M.D., 1977) | |||
|occupation = Physician | |||
|website = http://www.nrimed.com | |||
}} | |||
'''Edward Tobinick''' M.D. is an American ], ], and ], who invented the use of the drug ] for chronic neurological dysfunction after ] and ],<ref>{{cite news |last=Singh |first=Anita| title= Andrew Marr: how having a stroke changed my marriage for the better |url=https://www.telegraph.co.uk/news/2017/02/07/andrew-marr-having-stroke-changed-marriage-better/ |accessdate=November 17, 2018 |newspaper=]|date=February 7, 2017 }}</ref><ref>{{cite news |publisher=Springer Select |date=October 31, 2012 |title=New hope for survivors of stroke and traumatic brain injury | url=https://www.springer.com/about+springer/media/springer+select?SGWID=0-11001-6-1394543-0 |accessdate=November 17, 2018 }}</ref> with multiple issued U.S. and foreign patents, including U.S. patent 8,900,583. | |||
== Selected publications == | |||
{| class="wikitable" style="font-size:90%" | |||
|- style="text-align:center;" | |||
! style="background:#B0C4DE;" | Year | |||
! style="background:#B0C4DE;" | Article | |||
! style="background:#B0C4DE;" | Journal / Textbook | |||
|- | |||
| rowspan="1" | 2010 || || Expert Review of Neurotherapeutics 2010 Jun;10(6):985-1002. | |||
|- | |||
| rowspan="1" | 2011 || || CNS Drugs 2011, 25(2): p. 145-55. | |||
|- | |||
| rowspan="1" | 2012 || || CNS Drugs 2012, 26(12): p. 1051–70. | |||
|- | |||
| rowspan="1" | 2014 || || CNS Drugs 2014, 25(2): p. 145-55. | |||
|- | |||
| rowspan="1" | 2014 || || Clin Drug Investig 2014, 34(5): p. 361-6. | |||
|- | |||
| rowspan="1" | 2016 || || CNS Drugs 2016 Jun;30(6):469-80. | |||
|- | |||
| rowspan="1" | 2017 || || New Therapeutics for Traumatic Brain Injury, K.A. Heidenreich, Editor. 2017, Academic Press/Elsevier: New York. | |||
|- | |||
| rowspan="1" | 2018 || || Expert Review of Neurotherapeutics 2018, 18(6): p. 453-455. | |||
|} | |||
==References== | |||
{{Reflist}} | |||
== Selected patents== | |||
{| class="wikitable" style="font-size:90%" | |||
|- style="text-align:center;" | |||
! style="background:#B0C4DE;" | Year Issued | |||
! style="background:#B0C4DE;" | Inventor | |||
! style="background:#B0C4DE;" | Title | |||
! style="background:#B0C4DE;" | Country | |||
|- | |||
| rowspan="1" | 2009 || Edward Tobinick || || US | |||
|- | |||
| rowspan="1" | 2014 || Edward Tobinick || || US | |||
|} | |||
{{Authority control}} | |||
{{DEFAULTSORT:Tobinick, Edward}} | |||
] | |||
] | |||
] |
Latest revision as of 16:29, 9 April 2021
Redirect to: